APA (7th ed.) Citation

CW, F., A, C., S, G., A, G., C, T., M, S., . . . AW, L. (2022). Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide. Leukemia & lymphoma, 63(8), 1925. https://doi.org/10.1080/10428194.2022.2042686

Chicago Style (17th ed.) Citation

CW, Freyer, et al. "Letermovir Vs. High-dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical or Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Receiving Post-transplant Cyclophosphamide." Leukemia & Lymphoma 63, no. 8 (2022): 1925. https://doi.org/10.1080/10428194.2022.2042686.

MLA (9th ed.) Citation

CW, Freyer, et al. "Letermovir Vs. High-dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical or Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Receiving Post-transplant Cyclophosphamide." Leukemia & Lymphoma, vol. 63, no. 8, 2022, p. 1925, https://doi.org/10.1080/10428194.2022.2042686.